ライフサイエンスコーパス: therapeutic range

1 ssion, ideally yielding factor levels in the therapeutic range.

2 l normalized ratio (INR) elevation above the therapeutic range.

3 in serum were within or above the suggested therapeutic range.

4 ged delay in return of the INR to within the therapeutic range.

5 tion of genetically corrected cells into the therapeutic range.

6 tion of genetically corrected cells into the therapeutic range.

7 rates of anticoagulation and similar time in therapeutic range.

8 hours, maintaining plasma levels within the therapeutic range.

9 was established as the lower margin for the therapeutic range.

10 elevant bleeding followed closely by time in therapeutic range.

11 INR variability, followed closely by time in therapeutic range.

12 e was positively associated with time in the therapeutic range.

13 culatory concentration of drugs within their therapeutic range.

14 s effectiveness relies on maintaining INR in therapeutic range.

15 at 1 and 3 months and percentage of time in therapeutic range.

16 thromboplastin time (p = .002) close to the therapeutic range.

17 dard of care, warfarin, by improving time in therapeutic range.

18 alation was 331 ng/mL, within the postulated therapeutic range.

19 e or fewer infusions to be maintained in the therapeutic range.

20 ed well with each other and with established therapeutic ranges.

21 s in whole blood throughout their individual therapeutic ranges.

22 to develop optimal dosing schedules based on therapeutic ranges.

23 from 0.03 to 0.35 microM, which falls in the therapeutic range (0.01-10 microM), and a limit of detec

24 , (2) intravenous heparin maintained in the "therapeutic" range (0.2 to 0.5 U/mL plasma), and (3) "ex

25 lenges of maintaining serum levels in a safe therapeutic range (1-3muM).

26 than, within, or greater than a prespecified therapeutic range (1.5-2.5 times control), respectively.

27 activity with carbamazepine levels above the therapeutic range (15.4-17.2 mg/ml), but the remaining f

28 he international normalized ratio within the therapeutic range (2.0-3.0) for 6 months.

29 3.5 to 8.4 mg/l, which was within the normal therapeutic range (4-12 mg/l).

30 ts with liver disease had lower mean time in therapeutic range (53.5%) when compared with patients wi

31 h a score of zero had modestly lower time in therapeutic range (56.7%) and no increase in hemorrhages

32 ersus 42% at 3 months; percentage of time in therapeutic range 69% versus 58%, 71% versus 59%, respec

33 Outcomes included percent time in therapeutic range, a measure of anticoagulation control,

34 st human tumor xenografts showed an improved therapeutic range (active/toxic dose in mg/kg body weigh

35 INR more than or equal to the lower limit of therapeutic range, adding either early INRs or genotypes

36 leeding was a combination of percent time in therapeutic range and INR variability (odds ratio of 4.3

37 red, drug levels generally remain within the therapeutic range and lactate concentrations are not sub

38 However, it has a narrow therapeutic range and the one or more underlying mechani

39 challenging in children because of a narrow therapeutic range and wide inter- and intra-individual v

40 Only 3 studies used a validated aPTT therapeutic range, and 11 studies used a range that incl

41 abolized by cytochrome P450 2C, has a narrow therapeutic range, and is a commonly used antiepileptic

42 mus or cyclosporine levels that exceeded the therapeutic range, and none had other clinical evidence

43 vulsant drug levels in the upper half of the therapeutic range, and were not taking any other drugs t

44 With the narrow therapeutic range associated with most anticancer drugs,

45 h and 3 months and for percentage of time in therapeutic range at 3 months.

46 widely used anticoagulant that has a narrow therapeutic range because of both genetic and environmen

47 ound a significant difference in the time in therapeutic range between the pharmacogenetic and standa

48 acrolimus trough concentrations in the usual therapeutic range can lead to elevated unbound concentra

49 The percentage of time in the therapeutic range during the first 4 weeks after the ini

50 As antibiotic concentrations decline below a therapeutic range, filamentous bacteria begin to divide

51 nsitive to methylphenidate, and the accepted therapeutic range for adults is an overshoot.

52 chronic treatment (well within the accepted therapeutic range for adults), produced significant depr

53 An INR of 2 to 3 is the recommended therapeutic range for all indications except for the pre

54 resulted in plasma concentrations within the therapeutic range for calpain inhibition.

55 the test results, and establishment of a PFT therapeutic range for each antiplatelet drug should be c

56 d to 25 mug L(-1) diclofenac) was within the therapeutic range for humans.

57 which declined, but remained above the human therapeutic range for over 9 months.

58 for gamma-globin expression approaching the therapeutic range for sickle cell anemia and beta thalas

59 We hypothesized that the time in therapeutic range for tecarfarin will exceed values usua

60 mL) levels within 30 min and remained in the therapeutic range for the entire 24-h period.

61 olimus trough concentration) and TAC time in therapeutic range for the risk of dnDSAs in a cohort of

62 The time in therapeutic range for the warfarin group was 66%.

63 canine factor IX (cFIX) concentrations at a therapeutic range for up to 2.5 months and normalization

64 ernational normalized ratio (INR) was in the therapeutic range from day 4 or 5 through day 28 of ther

65 Study outcomes included optimal time in therapeutic range >/=65% and clinical events.

66 zed ratio control was excellent (time in the therapeutic range >72.6%).

67 Time in the therapeutic range has been inversely correlated with maj

68 t block of peak INa at levels well below the therapeutic range (IC50 of 6.8+/-0.4 micromol/L).

69 e initial drug blood serum levels within the therapeutic range in children and adjusted throughout th

70 y and found no difference in the time in the therapeutic range in patients randomized to vitamin K co

71 nced patients assigned warfarin, the time in therapeutic range (international normalized ratio 2.0 to

72 mortality amongst warfarin users, if time in therapeutic range is poor.

73 activated partial thromboplastin time (aPTT) therapeutic range is required to ensure administration o

74 rmalized ratio control was poor (time in the therapeutic range <57.1%).

75 onal normalized ratio control (i.e., time in therapeutic range <65%) exhibited a faster decline in GF

76 t of higher rates of dnDSAs, and TAC time in therapeutic range may be a valuable strategy to stratify

77 of anticoagulation in patients to a set INR therapeutic range may be less secure than anticipated.

78 how that CBZ, at concentrations in the human therapeutic range, normalizes the voltage dependence of

79 Only 10.9% of patients had time in therapeutic range of <45%.

80 TAC time in the therapeutic range of <60% was associated with dnDSAs (OR

81 We recommend a day 0 therapeutic range of 0.2 to 0.4 mug/mL.

82 f response or neurotoxicity by identifying a therapeutic range of 1.5 mg/L (>85% probability of respo

83 me measure was the percentage of time in the therapeutic range of 2.0 to 3.0 for the international no

84 The simulation predicted a mean time in therapeutic range of 70.6% and 72.2% (P=0.47) in the sta

85 A therapeutic range of adalimumab trough levels of 3.51 mg

86 one demonstrated CsA blood levels within the therapeutic range of human renal transplant patients.

87 n the case of epilepsy because of the narrow therapeutic range of most AEDs; clinical principles of p

88 50%, respectively, but were still within the therapeutic range of preclinical models.

89 in G6PD-deficient individuals to define the therapeutic range of primaquine to enable the safe roll-

90 We also identified the therapeutic range of rAAV.miS1 that could prevent or rev

91 that the R15E,K156Y mutations may extend the therapeutic range of t-PA.

92 hat PEGylation can significantly improve the therapeutic range of tTF-NGR.

93 useful for the detection of protamine in the therapeutic range of undiluted human blood.

94 Therapeutic ranges of 1.5 to 2.5 times the control value

95 sted drugs, which is sufficient to cover the therapeutic ranges of these drugs.

96 Mean time in therapeutic range on warfarin was 70.8% (SD 27.4).

97 thium maintenance therapy (lithium levels in therapeutic range) on the rate of change in eGFR over ti

98 Most aPTT values were above therapeutic range or beyond measuring limit and thus of

99 rt continued use of INR variability, time in therapeutic range, or both for research and quality assu

100 a decreased time to the first INR within the therapeutic range (P=0.02) and to the first INR of more

101 ctor of the time to the first INR within the therapeutic range (P=0.57) but was a significant predict

102 n patients with increased individual time in therapeutic range (regression coefficient, 0.03; 95% con

103 (p < .0001 vs. placebo) within or above the therapeutic range, respectively, these did not decrease

104 ess of the age of the patient, where time in therapeutic range should be > or =65%.

105 hat oral methylphenidate at doses within the therapeutic range significantly increases extracellular

106 or IX concentrations, while remaining in the therapeutic range, slowly declined by 95% over a period

107 s on warfarin and amiodarone had time in the therapeutic range that was lower than patients not on am

108 es were the time to the first INR within the therapeutic range, the time to the first INR of more tha

109 ood and plasma levels were maintained within therapeutic ranges throughout this trial.

110 sensitivity (time to INR >/= lower limit of therapeutic range; time to INR > 4; and first stable war

111 examine the relationship between time in the therapeutic range (TTR) and clinical outcomes in heart f

112 Percent time in therapeutic range (TTR) and international normalized rat

113 patients receiving warfarin, percent time in therapeutic range (TTR) and international normalized rat

114 BLED could be improved incorporating time in therapeutic range (TTR) in warfarin-treated patients.

115 Time in Therapeutic Range (TTR) was available in only 18.7% of p

116 illation (AF) patients, reflected by time in therapeutic range (TTR).

117 ects in relation to 2 predictions of time in therapeutic range (TTR).

118 comparisons with warfarin arms with times in therapeutic range (TTRs) of 55.2% to 64.9%, making the r

119 4 weeks, the mean percentage of time in the therapeutic range was 45.2% in the genotype-guided group

120 The mean time in the therapeutic range was 53.7% overall and improved with ti

121 patients receiving warfarin, the time in the therapeutic range was 63.5%.

122 The mean percentage of time in the therapeutic range was 67.4% in the genotype-guided group

123 rin treatment, the mean interpolated time in therapeutic range was 71.4%.

124 nternational normalized ratio was within the therapeutic range was higher in the intervention group t

125 patients, the mean percentage of time in the therapeutic range was less in the genotype-guided group

126 anticoagulants when the centre-based time in therapeutic range was less than 66% than when it was 66%

127 Frequency of INR testing and time in the therapeutic range were analyzed by age, sex, length of t

128 first in which concentrations of ASA in the therapeutic range were found to significantly reduce int

129 stemic embolism risk and a lower time in the therapeutic range when used with warfarin.